-
Targeting both domestic and foreign markets, pharmaceutical companies are actively deploying antidepressant drugs
Time of Update: 2021-12-08
According to relevant statistics, in 2019, the sales of terminal antidepressant drugs in public medical institutions in China increased by 10% year-on-year, exceeding 9 billion yuan .
According to statistics, there are currently 4 new antidepressant drugs developed and approved by domestic pharmaceutical companies.
-
Or focus on core business, or increase market share...Pharmaceutical companies will sell more frequently
Time of Update: 2021-12-08
Another example is Tianyao's recent announcement that Fosun Pharma intends to transfer its 25 shares of Tianjin Pharmaceutical Group, the controlling shareholder of the company, to Jinyao Group, the indirect controlling shareholder of the company, at a price of 1.
-
The pharmaceutical equipment industry ushered in a new round of growth, and the high-end market has become a new growth point for performance
Time of Update: 2021-12-08
It clearly stated that in the future, it will continue to implement the development strategy of "one vertical, one horizontal and one platform", leverage the synergy effects of various subsidiaries, increase investment in research and development and advanced manufacturing technology, and actively seize market opportunities in AI and intelligent equipment, and Steadily promote the construction of production capacity, and strive to achieve the strategic goal of reaching 20 billion yuan in sales in 2030 .
-
The pharmaceutical and biological sector has fallen by 7% since October. Is there still a chance to get on the car?
Time of Update: 2021-12-08
Judging from the attitudes of many fund managers and industry researchers, they generally believe that the current valuation of the pharmaceutical sector is at a relatively reasonable level, and there are more structural opportunities in the sector that are worth grasping .
-
Nearly 50,000 fined OTC pharmacies for overdue sales
Time of Update: 2021-12-08
In case of selling inferior drugs, the illegal income from the sale shall be confiscated, and a fine of ten to twenty times the value of the illegally sold drugs shall be imposed; if the value of the illegally retailed drugs is less than 10,000 yuan, it shall be calculated as 10,000 yuan .
-
The 2021 national talks are on the spot: a variety of PD-(L)1 confrontation BMSs are absent; CAR-T has not appeared in ADC, small molecule inhibitors are hotly talked...
Time of Update: 2021-12-08
Although the final results of the negotiations have not yet been released, the share prices of domestic PD-1 companies Hengrui, Junshi, Cinda, and BeiGene have soared after the medical insurance negotiations in the morning.
-
Heavy document is released, "API-preparation integration" enterprises welcome bright moments
Time of Update: 2021-12-08
In the past 5-10 years, the leading intermediates and API companies have been The quality management, cost control and other advantages accumulated in the process of expanding and regulating the market will help relevant companies to enrich their product structure in the medium term, and achieve forward integration and business model expansion along the industrial chain .
-
The API industry welcomes the new policy, the industry: good for the pharmaceutical equipment industry
Time of Update: 2021-12-08
This may help force domestic API production equipment manufacturers to increase R&D investment, continue to obtain new breakthroughs in the high-end field, and promote the better development of the API industry .
-
Multinational pharmaceutical companies release third-quarter financial reports: Pfizer and Merck have outstanding performance
Time of Update: 2021-12-08
534 billion; sales of GARDASIL/GARDASIL 9 (HPV vaccine) increased by 68% year-on-year to US$1.
Among them, the total revenue of Roche Diagnostics in the first three quarters increased by 38% year-on-year to 13.
-
The biopharmaceutical industry accelerates its development towards high quality, and the performance of pharmaceutical machinery companies may usher in new growth
Time of Update: 2021-12-08
For example, Jiangsu Province recently issued "Several Policies and Measures on Promoting the High-Quality Development of the Province’s Biomedicine Industry", which clearly stated that by 2024, the basic capabilities of Jiangsu’s biomedical industry and the modernization level of the industrial chain must continue to be improved.
-
The State Food and Drug Administration approves the listing of Yinqiao Qingre Tablets, an innovative Chinese medicine drug
Time of Update: 2021-12-08
On November 10, the State Food and Drug Administration issued an announcement stating that it had recently approved the registration application for Yinqiao Qingre tablets . Jiangsu Kangyuan Pharma
-
The medical insurance adjustment will be completed before the end of the year. The industry recommends grasping the investment opportunities of innovative drugs and CXO
Time of Update: 2021-12-08
After the price drop, third-party data pointed out that the drugs included in the medical insurance catalog after medical insurance negotiations from 2017 to 2019 have achieved 128%, 337%, and 39% growth in sales in 2020 relative to the year of inclusion .
-
Deepen cooperation!
Time of Update: 2021-12-08
They continue to increase their investment in China, try their best to meet the unmet medical needs of Chinese patients, and at the same time accelerate the pace of their innovative products entering the market, ensure the demand for clinical treatment, and expand the availability of drugs .
-
The tens of billions of migraine drugs market will usher in new changes!
Time of Update: 2021-12-08
It is understood that in addition to Pfizer's continuous work on CGRP receptor inhibitors, companies such as Amgen and Teva have also begun to develop new CGRP targeted drugs .
As a new type of drug, migraine drugs based on CGRP antibodies will have a huge space for future development .
-
Green development has become the general trend of the industry, and pharmaceutical companies are taking multiple measures to respond
Time of Update: 2021-12-08
Under the background that the country vigorously promotes green environmental protection and sustainable development, the construction of China's ecological civilization has entered a period of accele
-
Guangdong and Qinghai issued notices on drug quality sampling inspections for 7 varieties and 8 batches that did not meet the requirements
Time of Update: 2021-12-08
From November 10th to 11th, the drug regulatory bureaus of Guangdong and Qinghai provinces issued drug random inspection information notices. The notice showed that 47 batches of 39 varieties in Guan
-
The policy is to vacate the cage and change the bird, and the domestic innovative drugs may usher in a dividend period in the next ten years
Time of Update: 2021-12-08
In addition, industry insiders also said that in recent years, the introduction of policies such as import "zero tariff", review and approval system reform, consistency evaluation, and medical insurance negotiations are forcing pharmaceutical companies to develop in the direction of innovation .
-
Gale announced that the Phase II clinical trial application of ASC22 (envolimab) for immune reconstitution/functional cure of human immunodeficiency virus type 1 (HIV-1) infected persons has been approved by the State Food and Drug Administration of China
Time of Update: 2021-12-08
(Hong Kong Stock Exchange code: 1672) today announced that its ASC22 (Envolimab) Phase II clinical trial application has been approved by China Approved by the National Medical Products Administration (NMPA) as a new indication for immune reconstitution/functional cure for people infected with human immunodeficiency virus type 1 (HIV-1) .
-
Qinhao Pharmaceutical's SHP2 inhibitor was approved for clinical use
Time of Update: 2021-12-08
Article source: Pharmaceutical GuanlanOn November 10, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that the Class 1 new drug GH21 capsules declared by Qin Hao Medicine had obtained the implied license for clinical trials and planned to be developed for advanced solid tumors .
-
With favorable policies, Chinese medicine will play an important role in children's health care services
Time of Update: 2021-12-08
In addition, in May this year, the National Health Commission and the State Administration of Traditional Chinese Medicine also jointly issued the "Implementation Plan for Promoting Chinese Medicine in the Field of Maternal and Child Health (2021-2025)", which clearly stated that they would promote the development of Chinese medicine services in maternal and child health institutions.